clinical trial · NCT04826172
Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)
Imbria Pharmaceuticals, Inc.·phase2·completed·n = 58
IschemiaCoronary Artery DiseaseIMB-1018972Placebo
brief summary
The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.
started
Apr 23, 2021
primary completion
Sep 21, 2023
completion
Sep 21, 2023
last updated
Apr 23, 2024
official title
A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol